Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov
Condition: Solid Tumors
Study Type: Interventional
Phase: Phase I
Study Start Date: 01/14/2013
Study Completion Date: TBD
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in subjects with selected tumor indications. New recruitment is open for all active cohorts.
Active cohorts: urothelial carcinoma (efficacy) and gastric/gastroesophageal junction (GEJ) cancer (third line).
Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC), and renal cell carcinoma (RCC, first line).